Cargando…
Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer
Manipulation of immune system toward the rejection of established cancers has become the standard of care in some patients. Here we propose the development of an in situ autologous cancer vaccine, inCVAX, for the treatment of hepatocellular cancer (HCC). inCVAX is based on the induction of local imm...
Autores principales: | Qi, Xiaoqiang, Lam, Samuel SK, Liu, Dai, Kim, Dae Young, Ma, Lixin, Alleruzzo, Lu, Chen, Wei, Hode, Tomas, Henry, Carolyn J, Kaifi, Jussuf, Kimchi, Eric T, Li, Guangfu, Staveley-O’Carroll, Kevin F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027967/ https://www.ncbi.nlm.nih.gov/pubmed/27656328 http://dx.doi.org/10.4172/2155-9899.1000438 |
Ejemplares similares
-
Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018) -
Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response
por: Qi, Xiaoqiang, et al.
Publicado: (2020) -
Nanoliposome C6‐Ceramide in combination with anti‐CTLA4 antibody improves anti‐tumor immunity in hepatocellular cancer
por: Qi, Xiaoqiang, et al.
Publicado: (2022) -
PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer
por: Manjunath, Yariswamy, et al.
Publicado: (2019) -
Tumor-Cell–Macrophage Fusion Cells as Liquid Biomarkers and Tumor Enhancers in Cancer
por: Manjunath, Yariswamy, et al.
Publicado: (2020)